Esfahani, M.K.M.; Alavi, S.E.; Cabot, P.J.; Islam, N.; Izake, E.L.
PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells. Pharmaceutics 2021, 13, 1605.
https://doi.org/10.3390/pharmaceutics13101605
AMA Style
Esfahani MKM, Alavi SE, Cabot PJ, Islam N, Izake EL.
PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells. Pharmaceutics. 2021; 13(10):1605.
https://doi.org/10.3390/pharmaceutics13101605
Chicago/Turabian Style
Esfahani, Maedeh Koohi Moftakhari, Seyed Ebrahim Alavi, Peter J. Cabot, Nazrul Islam, and Emad L. Izake.
2021. "PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells" Pharmaceutics 13, no. 10: 1605.
https://doi.org/10.3390/pharmaceutics13101605
APA Style
Esfahani, M. K. M., Alavi, S. E., Cabot, P. J., Islam, N., & Izake, E. L.
(2021). PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells. Pharmaceutics, 13(10), 1605.
https://doi.org/10.3390/pharmaceutics13101605